November 10, 2017 / 1:15 PM / 6 months ago

BRIEF-Aduro Biotech ‍announces data from preclinical studies with ADU-1604

Reuters Staff

1 Min Read

Nov 10 (Reuters) - Aduro Biotech Inc

* Aduro Biotech Inc - ‍announced data from preclinical studies with ADU-1604, company’s humanized anti-CTLA-4 monoclonal antibody

* Aduro Biotech - ‍data from studies demonstrate potency of ADU-1604 and ability to inhibit tumor growth, enhance T cell-dependent antibody responses Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below